DBV Technologies SA
DBV
ISIN FR0010417345 / Valor 2857349
DBV Technologies SA
UMushroom community rating:
About company
DBV Technologies SA is a clinical-stage biopharmaceutical company based in France that develops allergy immunotherapies using a proprietary epicutaneous delivery platform (EPIT) designed to administer allergens via a skin patch to induce desensitization while avoiding systemic exposure. Its most advanced program is Viaskin Peanut, a patch intended to treat peanut allergy, and the company has extended the EPIT approach to other food and environmental allergens in its pipeline. DBV focuses on clinical development, regulatory filings and potential commercialization of these immunotherapies, and is publicly listed in Europe and the United States.
Summarized from source with an LLMView SourceSector: HealthcareKey figures
Performance
Volatility
618 M
Market cap (USD)
1,226,325
Daily traded volume (Shares)
/
1 day high/low (USD)
52 weeks high/low (USD)
Dividend ex-date
Dividend (USD)
Dividend yield (p.a.)
Est dividend (USD)
Est dividend yield
P/E ratio
Est P/E ratio
EPS (USD)
Est EPS (USD)
Ratings & reviews
EQUITIES OF THE SAME SECTOR
